Economic burden of patients with leading cancers in China: a cost-of-illness study

Economic burden of patients with leading cancers in China: a cost-of-illness study

Abstract Background China accounts for 24% of newly diagnosed cancer cases and 30% of cancer-related deaths worldwide. Comprehensive analyses of the economic burden on patients across different cancer treatment phases, based on empirical data, are lacking. This study aims to estimate the financial b...

Full description

Bibliographic Details
Main Authors: Ziting Wu, Yiwen Yu, Feng Xie, Qiushi Chen, Zhong Cao, Simiao Chen, Gordon G. Liu
Format: Article
Language:English
Published: BMC 2024-09-01
Series:BMC Health Services Research
Subjects:
Cost-of-illness
Cancer costs
China
Treatment phases
Online Access:https://doi.org/10.1186/s12913-024-11514-x

Internet

https://doi.org/10.1186/s12913-024-11514-x

Similar Items